Paper Details

  1. Home
  2. Paper Details

A Comparison of New Pharmacological Agents for the Treatment of Obesity.

Author: MegyeriJade, NufferWesley, TrujilloJennifer M

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Four new pharmacological agents for managing overweight and obesity have been approved: phentermine/topiramate ER, naltrexone/bupropion, liraglutide, and lorcaserin. Phentermine/topiramate ER had the best overall average weight loss, followed by naltrexone/bupropion, liraglutide, and lorcaserin. Most side effects were gastrointestinal in nature, with liraglutide having the highest reported rates and lorcaserin the lowest.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To review and compare the phase 3 clinical trial evidence on the 4 new pharmacological agents approved for the management of overweight and obesity. DATA SOURCES: Searches were performed (from 1966 through January 2016) in PubMed/MEDLINE, Scientific Citation Index, and product package in...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1177/1060028016634351

データ提供：米国国立医学図書館（NLM）

Navigating the Desert of Obesity Treatment

As a seasoned traveler in the vast desert of medical research, I’ve often encountered the challenges of weight management. It’s a complex and multifaceted issue, like a sandstorm constantly shifting the landscape of our health. This study, like a well-charted map, guides us through the landscape of new pharmacological agents for treating obesity.

The Comparative Oasis of Weight Loss Medications

The researchers, like meticulous cartographers, meticulously analyzed the results of clinical trials for four new medications approved for weight management: phentermine/topiramate ER, naltrexone/bupropion, liraglutide, and lorcaserin. While there were no head-to-head comparisons, the study revealed that phentermine/topiramate ER demonstrated the most promising results, followed by naltrexone/bupropion, liraglutide, and lorcaserin. The study also highlighted the importance of individualized treatment, recognizing that no single medication is a one-size-fits-all solution.

The Health Implications of a Balanced Approach

It’s important to recognize that while these medications can be helpful tools in the quest for weight management, they are not a magic bullet. A holistic approach, like a caravan navigating the desert, requires a combination of medication, lifestyle changes, and personalized guidance from a healthcare professional. This study serves as a reminder that the journey to a healthier weight is often a long and winding one, requiring patience, persistence, and a commitment to well-being.

Dr. Camel’s Conclusion

This study, like a captivating desert story, offers a glimpse into the evolving landscape of weight management. It underscores the importance of personalized care, evidence-based medicine, and a holistic approach to achieve lasting health outcomes. As we continue to navigate the desert of obesity treatment, we must remain open to new discoveries and embrace a journey of continuous learning and adaptation.
Date :
  1. Date Completed 2016-10-27
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

26887340

DOI: Digital Object Identifier

10.1177/1060028016634351

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.